Inozyme Pharma, Inc. (INZY)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Douglas A. Treco Ph.D. | CEO & Chairman | 552.02k | -- | 1958 |
| Mr. Axel Bolte M.B.A., M.Sc. | Co-Founder, Senior Advisor & Director | 40.89k | -- | 1972 |
| Mr. Sanjay S. Subramanian M.B.A., M.S. | CFO, Head of Business Development, Principal Accounting Officer & Corporate Secretary | 607.38k | -- | 1976 |
| Dr. Matthew Winton Ph.D. | Senior VP & COO | 602.1k | -- | 1978 |
| Dr. Demetrios Braddock M.D., Ph.D. | Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer | -- | -- | -- |
| Dr. Yves Sabbagh Ph.D. | Senior VP, Chief Scientific Officer & Chair of the Scientific Advisory Board | -- | -- | -- |
| Mr. Stefan Riley | Director of Investor Relations | -- | -- | -- |
| Ms. Gayle Gironda | Senior VP & Chief People Officer | -- | -- | -- |
| Mr. Stephen J. Di Palma M.B.A. | Consultant | -- | -- | 1959 |
| Ms. Petra Duda M.D., Ph.D. | Chief Medical Officer | -- | -- | -- |
Inozyme Pharma, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 67
Description
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Corporate Governance
Upcoming Events
August 4, 2025 at 12:30 PM UTC - August 8, 2025 at 12:30 PM UTC
Inozyme Pharma, Inc. Earnings Date